MYGN Myriad Genetics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MYGN

Price (delayed)

$27.39

Market cap

$2.11B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.98

Enterprise value

$2.18B

Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.myriad.com/

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing ...

Highlights

The EPS has grown by 34% from the previous quarter
The company's net income rose by 34% QoQ
The gross profit is down by 31% year-on-year but it is up by 2.3% since the previous quarter
The quick ratio has declined by 28% year-on-year but it has increased by 10% since the previous quarter
Myriad Genetics's revenue has decreased by 26% YoY
The company's equity fell by 10% YoY

Key stats

What are the main financial stats of MYGN
Market
Shares outstanding
77.05M
Market cap
$2.11B
Enterprise value
$2.18B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.39
Price to sales (P/S)
3.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.85
Earnings
Revenue
$566.1M
EBIT
-$190.2M
EBITDA
-$108.4M
Free cash flow
$10.7M
Per share
EPS
-$1.98
Free cash flow per share
$0.14
Book value per share
$11.47
Revenue per share
$7.45
TBVPS
$5.9
Balance sheet
Total assets
$1.34B
Total liabilities
$461.7M
Debt
$217.4M
Equity
$875.2M
Working capital
$180.2M
Liquidity
Debt to equity
0.25
Current ratio
2.21
Quick ratio
1.83
Net debt/EBITDA
-0.63
Margins
EBITDA margin
-19.1%
Gross margin
68.5%
Net margin
-26.1%
Operating margin
-35%
Efficiency
Return on assets
-10.6%
Return on equity
-16.5%
Return on invested capital
-39.5%
Return on capital employed
-16%
Return on sales
-33.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MYGN stock price

How has the Myriad Genetics stock price performed over time
Intraday
6.78%
1 week
-3.04%
1 month
-1.97%
1 year
91.81%
YTD
38.47%
QTD
-10.05%

Financial performance

How have Myriad Genetics's revenue and profit performed over time
Revenue
$566.1M
Gross profit
$387.7M
Operating income
-$198.4M
Net income
-$148M
Gross margin
68.5%
Net margin
-26.1%
The company's operating margin has shrunk by 55% YoY but it rose by 33% QoQ
The net margin has grown by 35% from the previous quarter but it has contracted by 34% YoY
The company's net income rose by 34% QoQ
The operating income rose by 32% QoQ but it fell by 15% YoY

Growth

What is Myriad Genetics's growth rate over time

Valuation

What is Myriad Genetics stock price valuation
P/E
N/A
P/B
2.39
P/S
3.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.85
The EPS has grown by 34% from the previous quarter
MYGN's price to book (P/B) is 40% higher than its last 4 quarters average of 1.6 and 7% higher than its 5-year quarterly average of 2.1
The company's equity fell by 10% YoY
The P/S is 43% higher than the last 4 quarters average of 2.4 and 32% higher than the 5-year quarterly average of 2.6
Myriad Genetics's revenue has decreased by 26% YoY

Efficiency

How efficient is Myriad Genetics business performance
The ROS has plunged by 58% YoY but it has grown by 31% from the previous quarter
The return on invested capital has declined by 39% year-on-year but it has grown by 23% since the previous quarter
Myriad Genetics's return on assets has increased by 32% QoQ but it has decreased by 10% YoY
MYGN's return on equity is up by 32% since the previous quarter but it is down by 17% year-on-year

Dividends

What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MYGN.

Financial health

How did Myriad Genetics financials performed over time
Myriad Genetics's total assets is 190% more than its total liabilities
Myriad Genetics's current ratio has decreased by 30% YoY and by 17% from the previous quarter
The quick ratio has declined by 28% year-on-year but it has increased by 10% since the previous quarter
The debt is 75% less than the equity
The debt has contracted by 26% YoY and by 25% from the previous quarter
The debt to equity is down by 24% since the previous quarter and by 17% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.